Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial
Authors: Tuñón José , González-Hernández Ignacio , Llanos-Jiménez Lucía , Alonso-Martín Joaquín , Escudier-Villa Juan M , Tarín Nieves , Cristóbal Carmen , Sanz Petra , Pello Ana M , Aceña Álvaro , Carda Rocío , Orejas Miguel , Tomás Marta , Beltrán Paula , Calero Rueda Marta , Marcos Esther , Serrano-Antolín José María , Gutiérrez-Landaluce Carlos , Jiménez Rosa , Cabezudo Jorge , Curcio Alejandro , Peces-Barba Germán , González-Parra Emilio , Muñoz-Siscart Raquel , González-Casaus María Luisa , Lorenzo Antonio , Huelmos Ana , Goicolea Javier , Ibáñez Borja , Hernández Gonzalo , Alonso-Pulpón Luis M , Farré Jerónimo , Lorenzo Óscar , Mahíllo-Fernández Ignacio , Egido Jesús 
Published: August 2016

Introduction

Decreased plasma vitamin D (VD) levels are linked to cardiovascular damage. However, clinical trials have not demonstrated a benefit of VD supplements on left ventricular (LV) remodelling. Anterior ST-elevation acute myocardial infarction (STEMI) is the best human model to study the effect of treatments on LV remodelling. We present a proof-of-concept study that aims to investigate whether VD improves LV remodelling in patients with anterior STEMI.

Methods and analysis

The VITamin D in Acute Myocardial Infarction (VITDAMI) trial is a multicentre, randomised, double-blind, placebo-controlled trial. 144 patients with anterior STEMI will be assigned to receive calcifediol 0.266 mg capsules (Hidroferol SGC)/15 days or placebo on a 2:1 basis during 12 months. Primary objective: to evaluate the effect of calcifediol on LV remodelling defined as an increase in LV end-diastolic volume ≥10% (MRI). Secondary objectives: change in LV end-diastolic and end-systolic volumes, ejection fraction, LV mass, diastolic function, sphericity index and size of fibrotic area; endothelial function; plasma levels of aminoterminal fragment of B-type natriuretic peptide, galectin-3 and monocyte chemoattractant protein-1; levels of calcidiol (VD metabolite) and other components of mineral metabolism (fibroblast growth factor-23 (FGF-23), the soluble form of its receptor klotho, parathormone and phosphate). Differences in the effect of VD will be investigated according to the plasma levels of FGF-23 and klotho. Treatment safety and tolerability will be assessed. This is the first study to evaluate the effect of VD on cardiac remodelling in patients with STEMI.

Ethics and dissemination

This trial has been approved by the corresponding Institutional Review Board (IRB) and National Competent Authority (Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)). It will be conducted in accordance with good clinical practice (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP)) requirements, ethical principles of the Declaration of Helsinki and national laws. The results will be submitted to indexed medical journals and national and international meetings.

Trial registration number

NCT02548364; Pre-results.